Research programme: endometriosis therapeutics - Bayer/Evotec
Latest Information Update: 02 Oct 2014
At a glance
- Originator Bayer HealthCare; Evotec AG
- Mechanism of Action
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Endometriosis
Most Recent Events
- 30 Sep 2014 Preclinical trials in Endometriosis in Germany (unspecified route)
- 02 Oct 2012 Early research in Endometriosis in Germany (unspecified route)